A prospective study of pregravid oral contraceptive use in relation to fetal growth

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 111, Issue 9, 2004, Pages 989-995

  Mucci, Lorelei A ^a   Lagiou, Pagona ^b   Hsieh, Chung Cheng ^c   Tamimi, Rulla ^a   Hellerstein, Susan ^d   Vatten, Lars ^e   Adami, Hans Olov ^f   Cnattingius, Sven ^f   Trichopoulos, Dimitrios ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRIOL; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

ADULT; ARTICLE; BIRTH WEIGHT; BLOOD ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; DATA ANALYSIS; DRUG FORMULATION; ESTRIOL BLOOD LEVEL; FEMALE; FETUS GROWTH; GESTATIONAL AGE; HORMONE DETERMINATION; HUMAN; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEWBORN; NORMAL HUMAN; ORAL CONTRACEPTION; PARITY; PLACENTA WEIGHT; PREGNANCY; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; QUESTIONNAIRE;

ADOLESCENT; ADULT; CONTRACEPTIVES, ORAL; EMBRYONIC AND FETAL DEVELOPMENT; FEMALE; GRAVIDITY; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; MALE; MATERNAL AGE; MATERNAL EXPOSURE; PRECONCEPTION CARE; PREGNANCY; PREGNANCY OUTCOME; PROSPECTIVE STUDIES;

EID: 4544341576     PISSN: 14700328     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2004.00232.x     Document Type: Article

References (24)

1. Borgelt-Hansen L. Oral contraceptives: an update on health benefits and risks. J Am Pharm Assoc 2001;41:875-886.
2. Burkman RT, Collins JA, Shulman LP, Williams JK. Current perspectives on oral contraceptive use. Am J Obstet Gynecol 2001;185:S4-S12.
3. Rothman KJ. Fetal loss, twinning and birth weight after oral-contraceptive use. N Engl J Med 1977;297:468-471.
4. Vessey M, Meisler L, Flavel R, Yeates D. Outcome of pregnancy in women using different methods of contraception. Br J Obstet Gynaecol 1979;86:548-556.
5. Alberman E, Pharoah P, Chamberlain G, Roman E, Evans S. Outcome of pregnancies following the use of oral contraceptives. Int J Epidemiol 1980;9:207-213.
6. Bracken MB, Srisuphan W. Oral contraception as a risk factor for preeclampsia. Am J Obstet Gynecol 1982;142:191-196.
7. Polednak AP, Janerich DT, Glebatis DM. Maternal exposure to exogenous sex hormones in relation to birth weight of offspring. Teratology 1983;27:223-229.
8. Peterson WF. Pregnancy following oral contraceptive therapy. Obstet Gynecol 1969;34:363-367.
9. Lipworth L, Hsieh CC, Wide L, et al. Maternal pregnancy hormone levels in an area with a high incidence (Boston, USA) and in an area with a low incidence (Shanghai China) of breast cancer. Br J Cancer 1999;79:7-12.
10. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 2002;94:32-38.
11. Speroff L, Glass RH, Kase NG. Clinical Gynelogic Endocrinology and Infertility, 5th edition. Baltimore, Maryland: Williams and Wilkins, 1994.
12. Kaijser M, Granath F, Jacobsen G, Cnattingius S, Ekbom A. Maternal pregnancy estriol levels in relation to anamnestic and fetal anthropometric data. Epidemiology 2000;11:315-319.
13. Mucci LA, Lagiou P, Tamimi RM, Hsieh CC, Adami HO, Trichopoulos D. Pregnancy estriol, estradiol, progesterone and prolactin in relation to birth weight and other birth size variables (United States). Cancer Causes Control 2003;14:311-318.
14. Bosetti C, Negri E, Trichopoulos D, et al. Long-term effects of oral contraceptives on ovarian cancer risk. Int J Cancer 2002;102:262-265.
15. Rodriguez GC, Walmer DK, Cline M, et al. Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Investig 1998;5:271-276.
16. Mueck AO, Seeger H, Graser T, Oettel M, Lippert TH. The effects of postmenopausal hormone replacement therapy and oral contraceptives on the endogenous estradiol metabolism. Horm Metab Res 2001;33:744-747.
17. Thadhani R, Stampfer MJ, Chasan-Taber L, Willett WC, Curhan GC. A prospective study of pregravid oral contraceptive use and risk of hypertensive disorders of pregnancy. Contraception 1999;60:145-150.
18. Lagiou P, Tamimi RM, Mucci LA, Adami HO, Hsieh CC, Trichopoulos D. Diet during pregnancy in relation to maternal weight gain and birth size. Eur J Clin Nutr 2004;58:231-237.
19. Hunter DJ, Manson JE, Colditz GA, et al. Reproducibility of oral contraceptive histories and validity of hormone composition reported in a cohort of US women. Contraception 1997;56:373-378.
20. Cole P, MacMahon B, Brown JB. Oestrogen profiles of parous and nulliparous women. Lancet 1976;2:596-599.
21. Bernstein L, Depue RH, Ross RK, Judd HL, Pike MC, Henderson BE. Higher maternal levels of free estradiol in first compared to second pregnancy: early gestational differences. J Natl Cancer Inst 1986;76:1035-1039.
22. Panagiotopoulou K, Katsouyanni K, Petridou E, Garas Y, Tzonou A, Trichopoulos D. Maternal age, parity, and pregnancy estrogens. Cancer Causes Control 1990;1:119-124.
23. Michels KB, Trichopoulos D, Robins JM, et al. Birthweight as a risk factor for breast cancer. Lancet 1996;348:1542-1546.
24. Fall CH, Osmond C, Barker DJ, et al. Fetal and infant growth and cardiovascular risk factors in women. BMJ 1995;310:428-432.